The article profiles the biotechnology company Receptor Biologix, which is attempting to develop an anti-cancer drug. One drug candidate, called Dimercept, is designed to couple with cancer cells, inhibiting signals that tell the cell to replicate, thus stemming the growth of cancer within a patient's body.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados